Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02118285 · ClinicalTrials.gov registry record · Phase 1
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02118285 is a Phase 1 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 2 participants.
The verdict
NCT02118285, a Phase 1 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a single center phase I trial designed to determine the maximum tolerated dose (MTD) of the oral IDO inhibitor INCB024360 when administered as part of a larger regimen of intraperitoneal (IP) delivery of haploidentical donor NK cells and IL-2 after a non-myeloablative cyclophosphamide/fludarabine (Cy/Flu) preparative regimen for the treatment of recurrent ovarian, fallopian tube, and primary peritoneal cancer.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL NK cells
- BIOLOGICAL IL-2
- DRUG INCB024360
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-07-28 |
| Est. Completion | 2015-11-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02118285
The ClinicalTrials.gov registry entry for NCT02118285 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02118285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02118285 about?
NCT02118285 is a clinical study titled "Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer". This is a single center phase I trial designed to determine the maximum tolerated dose (MTD) of the oral IDO inhibitor INCB024360 when administered as part of a larger regimen of intraperitoneal (IP) delivery of haploidentical donor NK cells and IL-2 after a non-myeloablative cyclophosphamide/fludar...
What is the current status of trial NCT02118285?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2014-07-28. Estimated completion is 2015-11-12.
What interventions are being tested in trial NCT02118285?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), NK cells (BIOLOGICAL), IL-2 (BIOLOGICAL), INCB024360 (DRUG).
Who is sponsoring clinical trial NCT02118285?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.